Corrêa, Paulo Roberto CeridóreoMiranda, Roqueline Rodrigues Silva deDuarte, Lucienir PainsSilva, Grácia Divina de FátimaVieira Filho, Sidney AugustoOkuma, Adriana AkemiCarazza, FernandoDíaz, José Andrés MorgadoPinge Filho, PhilenoYamauchi, Lucy MegumiNakamura, Celso VataruOgatta, Sueli Fumie Yamada2017-03-312017-03-312012CORRÊA, P. R. C. et al. Antimicrobial activity of synthetic bornyl benzoates against Trypanosoma cruzi. Pathogens and Global Health, v. 106, p. 107, 2012. Disponível em: <http://www.tandfonline.com/doi/full/10.1179/2047773212Y.0000000002>. Acesso em: 20 jan. 2017.2047-7732http://www.repositorio.ufop.br/handle/123456789/7506We report here for the first time the in vitro effects of (1S,2R,4S)-1,7,7-trimethyl-bicyclo[2.2.1]heptan-2-yl- 39,49,59-trimethoxy benzoate (1) and (1S,2R,4S)-1,7,7-trimethyl-bicyclo[2.2.1]heptan-2-yl benzoate (2) on the growth and ultrastructure of Trypanosoma cruzi. These two synthetic compounds exerted an antiproliferative effect on the epimastigote forms of the parasite. The ICs50/72h of two synthetic L-bornyl benzoates, 1 and 2, was 10.1 and 12.8 mg/ml, respectively. Both compounds were more selective against epimastigotes than HEp-2 cells. Ultrastructural analysis revealed intense cytoplasmic vacuolization and the appearance of cytoplasmic materials surrounded by membranes. The treatment of peritoneal macrophages with compounds 1 and 2 caused a significant decrease in the number of T. cruzi-infected cells. L-Bornyl benzoate derivatives may serve as a potential source for the development of more effective and safer chemotherapeutic agents against T. cruzi infections.en-USrestritoArtigo publicado em periodicohttp://www.tandfonline.com/doi/full/10.1179/2047773212Y.0000000002https://doi.org/10.1179/2047773212Y.0000000002